{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:22:39Z","timestamp":1760232159868,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Health and Human Services","award":["HHSO10020170011I"],"award-info":[{"award-number":["HHSO10020170011I"]}]},{"name":"Administration for Strategic Preparedness and Response","award":["HHSO10020170011I"],"award-info":[{"award-number":["HHSO10020170011I"]}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO10020170011I"],"award-info":[{"award-number":["HHSO10020170011I"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, recognizes that the evaluation of medical countermeasures under the Animal Rule requires well-characterized and reproducible animal models that are likely to be predictive of clinical benefit. Marburg virus (MARV), one of two members of the genus Marburgvirus, is characterized by a hemorrhagic fever and a high case fatality rate for which there are no licensed vaccines or therapeutics available. This natural history study consisted of twelve cynomolgus macaques challenged with 1000 PFU of MARV Angola and observed for body weight, temperature, viremia, hematology, clinical chemistry, and coagulation at multiple time points. All animals succumbed to disease within 8 days and exhibited signs consistent with those observed in human cases, including viremia, fever, systemic inflammation, coagulopathy, and lymphocytolysis, among others. Additionally, this study determined the time from exposure to onset of disease manifestations and the time course, frequency, and magnitude of the manifestations. This study will be instrumental in the design and development of medical countermeasures to Marburg virus disease.<\/jats:p>","DOI":"10.3390\/v14102291","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T02:54:25Z","timestamp":1666148065000},"page":"2291","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Natural History of Marburg Virus Infection to Support Medical Countermeasure Development"],"prefix":"10.3390","volume":"14","author":[{"given":"Jason E.","family":"Comer","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Brasel","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Massey","sequence":"additional","affiliation":[{"name":"Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Beasley","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-0542","authenticated-orcid":false,"given":"Chris M.","family":"Cirimotich","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, OH 43162, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Sanford","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, OH 43162, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Liang","family":"Chou","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, OH 43162, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-7743","authenticated-orcid":false,"given":"Nancy A.","family":"Niemuth","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, OH 43162, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Novak","sequence":"additional","affiliation":[{"name":"AmplifyBio, West Jefferson, OH 43162, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol L.","family":"Sabourin","sequence":"additional","affiliation":[{"name":"Tunnell Government Services, Inc., Supporting Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Merchlinsky","sequence":"additional","affiliation":[{"name":"CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Long","sequence":"additional","affiliation":[{"name":"Tunnell Government Services, Inc., Supporting Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Stavale","sequence":"additional","affiliation":[{"name":"CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-9506","authenticated-orcid":false,"given":"Daniel N.","family":"Wolfe","sequence":"additional","affiliation":[{"name":"CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"ref_1","unstructured":"Patel, P.R., and Shah, S. (2022). Ebola Virus, StatPearls."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.medmal.2014.08.005","article-title":"Case fatality rates of Ebola virus diseases: A meta-analysis of World Health Organization data","volume":"44","author":"Lefebvre","year":"2014","journal-title":"Med. Mal. Infect."},{"key":"ref_3","unstructured":"cdc.gov (2022, October 11). History of Marburg Virus Disease (MVD) Outbreaks, Available online: https:\/\/www.cdc.gov\/vhf\/marburg\/outbreaks\/chronology.html."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jones, M.E., Amman, B.R., Sealy, T.K., Uebelhoer, L.S., Schuh, A.J., Flietstra, T., Bird, B.H., Coleman-McCray, J.D., Zaki, S.R., and Nichol, S.T. (2019). Clinical, Histopathologic, and Immunohistochemical Characterization of Experimental Marburg Virus Infection in A Natural Reservoir Host, the Egyptian Rousette Bat (Rousettus aegyptiacus). Viruses, 11.","DOI":"10.3390\/v11030214"},{"key":"ref_5","first-page":"241","article-title":"A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the \u2019Animal Rule\u2019","volume":"65","author":"Glaze","year":"2015","journal-title":"Comp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S1021","DOI":"10.1093\/infdis\/jir339","article-title":"Pathogenesis of Marburg Hemorrhagic Fever in Cynomolgus Macaques","volume":"204","author":"Hensley","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1093\/infdis\/jiv095","article-title":"Immune Response to Marburg Virus Angola Infection in Nonhuman Primates","volume":"212","author":"Fernando","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e0138843","DOI":"10.1371\/journal.pone.0138843","article-title":"Dose Response of MARV\/Angola Infection in Cynomolgus Macaques following IM or Aerosol Exposure","volume":"10","author":"Johnston","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Blair, P.W., Keshtkar-Jahromi, M., Psoter, K.J., Reisler, R.B., Warren, T.K., Johnston, S.C., Goff, A.J., Downey, L.G., Bavari, S., and Cardile, A.P. (2018). Virulence of Marburg Virus Angola Compared to Mt. Elgon (Musoke) in Macaques: A Pooled Survival Analysis. Viruses, 10.","DOI":"10.3390\/v10110658"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e0215457","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples","volume":"14","author":"Rudge","year":"2019","journal-title":"PLoS ONE"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.3390\/v4123511","article-title":"Standardization of the Filovirus Plaque Assay for Use in Preclinical Studies","volume":"4","author":"Shurtleff","year":"2012","journal-title":"Viruses"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cross, R.W., Bornholdt, Z.A., Prasad, A.N., Woolsey, C., Borisevich, V., Agans, K.N., Deer, D.J., Abelson, D.M., Kim, D.H., and Shestowsky, W.S. (2022). Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. JCI Insight, 7.","DOI":"10.1172\/jci.insight.159090"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1038\/s41598-017-03910-7","article-title":"Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product","volume":"7","author":"Dowall","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"138ra81","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful Treatment of Ebola Virus\u2013Infected Cynomolgus Macaques with Monoclonal Antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature14442","article-title":"Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates","volume":"521","author":"Thi","year":"2015","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Alfson, K., Goez-Gazi, Y., Gazi, M., Staples, H., Mattix, M., Ticer, A., Klaffke, B., Stanfield, K., Escareno, P., and Keiser, P. (2021). Development of a Well-Characterized Rhesus Macaque Model of Ebola Virus Disease for Support of Product Development. Microorganisms, 9.","DOI":"10.3390\/microorganisms9030489"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wolf, J., Jannat, R., Dubey, S., Troth, S., Onorato, M., Coller, B.-A., Hanson, M., and Simon, J. (2021). Development of Pandemic Vaccines: ERVEBO Case Study. Vaccines, 9.","DOI":"10.3390\/vaccines9030190"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e0252874","DOI":"10.1371\/journal.pone.0252874","article-title":"Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease","volume":"16","author":"Niemuth","year":"2021","journal-title":"PLoS ONE"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Warren, T., Zumbrun, E., Weidner, J.M., Gomba, L., Rossi, F., Bannister, R., Tarrant, J., Reed, M., Lee, E., and Raymond, J.L. (2020). Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics. Viruses, 12.","DOI":"10.3390\/v12010092"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1128\/CVI.00288-12","article-title":"Development of an Inhalational Bacillus anthracis Exposure Therapeutic Model in Cynomolgus Macaques","volume":"19","author":"Henning","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1128\/AAC.04606-14","article-title":"Added Benefit of Raxibacumab to Antibiotic Treatment of Inhalational Anthrax","volume":"59","author":"Migone","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/10\/2291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:56:42Z","timestamp":1760144202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/10\/2291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["v14102291"],"URL":"https:\/\/doi.org\/10.3390\/v14102291","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2022,10,18]]}}}